![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 15, 13331-13337, April 12, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Pathology and Laboratory Medicine, British
Columbia's Children's Hospital and University of British Columbia,
4480 Oak Street, Vancouver, British Columbia V6H 3V4, Canada
Received for publication, December 17, 2001
Natural killer (NK) cells express an
activating receptor, 2B4, that enhances cellular cytotoxicity. Upon NK
cell activation by ligation of 2B4, the intracellular domain of 2B4
associates with the X-linked lymphoproliferative disease (XLP) gene
product, signaling lymphocytic activation molecule-associated
protein/SH2D1A (SAP/SH2D1A). Defective intracellular association of 2B4
with mutated SAP/SH2D1A is likely to underlie the defects in
cytotoxicity observed in NK cells from patients with XLP. We report
here a role for phosphoinositide 3-kinase (PI3K) in the recruitment
and association of SAP/SH2D1A to 2B4 in human NK cells. The activation of normal NK cells by ligation of 2B4 leads to the phosphorylation of
2B4, recruitment of SAP/SH2D1A, and association of the p85 regulatory
subunit of PI3K. The inhibition of PI3K enzymatic activity with either
wortmannin or LY294002 prior to 2B4 ligation does not alter the
association of 2B4 with the p85 subunit but prevents the recruitment of
SAP/SH2D1A to 2B4. In addition, PI3K inhibitors significantly diminish
the cytotoxic function of primary NK cells. This observed inhibition of
cytotoxicity, present in normal NK cells, was less apparent or absent
in NK cells derived from a patient with XLP. These data indicate that
the cytotoxicity of activated NK cells is mediated by the association
of 2B4 and SAP/SH2D1A, and that this association is dependent upon the
activity of PI3K.
Natural killer (NK)1 cells are an integral
component of the antiviral immune
response acting to limit viral
replication through both cellular cytotoxic mechanisms and the
secretion of cytokines (1, 2). A large number of activating and
inhibitory receptors are expressed on the surface of NK cells, and
there is a general agreement that the effector function of NK cells is
determined by a balance of positive and negative intracellular
signals (3, 4). An important activating receptor of NK cells is 2B4, a member of the CD2 subset of the immunoglobulin superfamily (5, 6). Upon 2B4 activation by a natural ligand, CD48, or with a monoclonal
antibody, NK cells are induced to augment their cytotoxicity, secrete
interferon- The cytoplasmic tail of 2B4 contains four tyrosine-based motifs that
allow for phosphorylation and subsequent binding by molecules containing src-homology 2 (SH2) domains (6, 10, 11). Thus, following stimulation, human 2B4 has been shown to be phosphorylated (12, 13) and associate with a number of SH2 proteins including the
SHP-1 and SHP-2 phosphatases (12, 14, 15) and p62dok (Dok1) (16)
as well as with the linker for the activation of T-lymphocytes (LAT),
an adaptor protein that acts as a substrate for SH2 proteins (17). In
addition, 2B4 associates with signaling lymphocytic activation
molecule-associated protein/SH2D1A (SAP/SH2D1A), an adaptor
molecule containing a single SH2 domain (18).
SAP/SH2D1A is expressed in both NK cells and T-lymphocytes, and the
mutations of SAP/SH2D1A are associated with the immunodeficiency syndrome, X-linked lymphoproliferative disease (XLP) (19-21).
Consistent with the expression of SAP/SH2D1A in NK cells and its
intracellular association with 2B4, XLP patients manifest defects in NK
cytotoxic function, particularly following 2B4 activation (18, 22-24). However, the detailed intracellular mechanisms by which SAP/SH2D1A influences 2B4 signaling and NK function are unclear, and in
particular, the involvement of phosphoinositide 3-kinase (PI3K) in
2B4-mediated cytotoxicity is unknown.
Class I PI3K, the isoform most linked to lymphocytes, comprises
both a catalytic (p110 In this study, we investigated the role of PI3K in the downstream
signaling events of 2B4 following the activation of primary human NK
cells. We show that the p85 regulatory subunit of PI3K associates with
2B4, and that the association of 2B4 with SAP/SH2D1A is abrogated by
the inhibition of PI3K enzymatic activity. We also provide evidence
that PI3K activity induced by 2B4 stimulation is absent in NK cells
expressing mutated SAP/SH2D1A. Finally, we show that PI3K inhibitors
diminish the cytotoxicity of NK cells obtained from healthy individuals
but have little or no effect on the cytotoxicity of NK cells from an
XLP patient.
Antibodies and Reagents--
Polyclonal antiserum to human
SAP/SH2D1A was produced by immunizing rabbits with a C-terminal peptide
(GTTGIREDPDVCLKAP) coupled to keyhole limpet hemocyanin
(ImmuneChem Pharmaceuticals, Vancouver, British Columbia,
Canada). Antibodies used included anti-2B4 (mAb C1.7, Biodesign
International, Saco, ME), anti-p85 (BD Transduction Laboratories,
Mississauga, Ontario, Canada), antiphosphotyrosine (4G10,
Upstate Biotechnology, Lake Placid, NJ), anti-CD3 fluorescein isothiocyanate, and anti-CD56 PE (BD PharMingen, Mississauga, Ontario,
Canada). Chemical reagents used were protease inhibitors mixture,
wortmannin, LY294002 (Sigma) and PD98059, protein kinase C inhibitor
(19-27), and Lck inhibitor PP2 (Calbiochem).
Natural Killer Cells--
The study was approved by the
University of British Columbia Clinical Research Ethics Board, and
informed consent was obtained from all subjects prior to blood
collection. NK cells were selected from peripheral blood using
RosetteSep (StemCell Technologies, Vancouver, British Columbia, Canada)
containing antibodies to CD3, CD36, CD4, CD66b, CD19, and glycophorin A
followed by Ficoll density gradient centrifugation. Cells were cultured
in complete medium (CM) consisting of RPMI 1640 medium supplemented
with 10% human serum, 10 units/ml penicillin, 100 µg/ml
streptomycin, 1 mM L-glutamine, 1%
nonessential amino acids, 5 × 10 Cytotoxicity Assays--
NK cells were prepared as
described above and used in either an inactivated (CM alone) or
activated (CM with anti-2B4 and IL-2) state as effector cells.
The target cells were either the NK-sensitive chronic myelogenous
leukemia cell line, K562 (ATCC, Manassas, VA), or the
NK-resistant lymphokine-activated killer-sensitive Burkitt's lymphoma
cell line, Raji (ATCC, Manassas, VA). Target cells were maintained in
RPMI 1640 medium with 10% fetal calf serum and labeled with
51Cr for 1 h. The effector to target ratio was
adjusted to 20:1 and/or 10:1 in a total volume of 200 µl. The cells
were incubated for 4 h at 37 °C, and 100 µl of supernatant
was removed from each well for Western Blots and Immunoprecipitations--
NK cells (5 × 106 cells) were incubated for 30 min at 4 °C with gentle
agitation in lysis buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.2 mM sodium vanadate, 0.2 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 0.5% Nonidet P-40, and protease inhibitors mixture). The preparation was centrifuged at 14,000 × g at 4 °C for 15 min, and the lysate was precleared by
incubation with protein A/G-agarose at 4 °C for 15 min to reduce the
nonspecific binding of proteins to agarose beads. The protein
concentration of the lysates was measured by the Bradford method, and
equal amounts were used in Western blots or immunoprecipitates. For
immunoprecipitates, the lysates were incubated overnight at 4 °C
with a 1:100 dilution of the relevant antibody. The immune complexes
were collected by the addition of protein A/G-agarose, and the pellet
was washed three times in immunoprecipitated buffer before suspension
in SDS sample buffer. Proteins were separated by SDS-PAGE, transferred onto polyvinylidene difluoride membranes, and blocked with 5% skim
milk in Tris-buffered saline containing 0.05% Tween 20 with the
exception of tyrosine phosphorylation experiments where 1% bovine
serum albumin was added to the Tris-buffered saline containing 0.05%
Tween 20. The membranes were incubated with primary antibody in
blocking buffer overnight at 4 °C and then with secondary
antibody for 2 h at room temperature before detection using either
a color development method (Bio-Rad) or ECL using SuperSignal WestPico substrate (Pierce). For all assays, wide range molecular weight standards were used (Bio-Rad).
Phosphatidylinositol Kinase Assay--
PI3K assays were
performed as described previously (30). NK cells were either left
intact or pretreated with 100 nM wortmannin as described
earlier and then were incubated in CM alone or CM with mAb C1.7 and
IL-2 (100 IU/ml) for 5 min. Cell lysates were immunoprecipitated with
mAb C1.7, and immunocomplexes were washed first with buffer containing
137 mM NaCl, 20 mM Tris base, pH 7.5, 1 mM CaCl2, 1 mM MgCl2,
0.1 mM sodium orthovanadate, and 1% Nonidet P-40 and then
with buffer containing 0.5 M LiCl, 100 mM
Tris-HCl, pH 7.5, and 1 mM sodium orthovanadate and finally with Tris/NaCl/EDTA buffer containing 0.1 mM
sodium orthovanadate. The protein complexes were mixed with 50 µl of
Tris/NaCl/EDTA buffer, 10 µl (20 µg) of
phosphatidylinositol 4,5-bisphosphate (Sigma), and 10 µl of
100 mM MgCl2. The reaction was started by the
addition of 30 µCi/sample of [ NK Cell Activation by Anti-2B4 Results in 2B4 Phosphorylation and
the Recruitment of SAP/SH2D1A in Normal but Not XLP NK
Cells--
Previous reports indicate that the activation of NK cell
lines by the ligation of 2B4 is followed by 2B4 phosphorylation and the
recruitment of SAP/SH2D1A (12, 17). Using NK cells from healthy
individuals, we found that activation of primary NK cells with an
antibody to 2B4 (31) results in 2B4 phosphorylation within 2 min of
stimulation (Fig. 1A) and the
recruitment of SAP/SH2D1A (Fig. 1B). The association of 2B4
and SAP/SH2D1A is present following ligation with anti-2B4 alone but is
significantly enhanced when IL-2 is present, suggesting a synergistic
interaction between 2B4 and IL-2 and also implying that downstream
pathways of IL-2 signaling are important for the recruitment of
SAP/SH2D1A (Fig. 1B). The association between 2B4 and
SAP/SH2D1A begins at 5 min following NK activation and persists at
least 20 min (Fig. 1C). In contrast, cells from an XLP
patient who carries an inactivating arginine to leucine (R55L) mutation
of SAP/SH2D1A (32) failed to recruit SAP/SH2D1A to 2B4 following
activation (Fig. 1D). The lack of association between 2B4
and SAP/SH2D1A was not because of an absolute lack of SAP/SH2D1A
expression in mutated cells, although there was a decreased level of
expression seen (Fig. 1E).
2B4 Associates with the p85 Subunit of PI3K and Activated PI3K
Recruit SAP/SH2D1A to 2B4--
Because PI3K has been
previously implicated in both NK cytotoxicity (29) and chemotaxis (30,
33), we investigated whether PI3K associates with 2B4 in activated NK
cells. The PI3K isoform in lymphocytes consists of a regulatory subunit
p85, which contains two SH2 domains, and a catalytic subunit p110,
which functions as a lipid kinase. The presence of SH2 domains within
the regulatory subunit suggests a potential association between
phosphorylated 2B4 and PI3K. NK cells cultured from healthy individuals
were either left inactivated or activated briefly with anti-2B4 and IL-2. Cell lysates were immunoprecipitated with anti-2B4 and
immunoblotted with anti-p85. Fig.
2A indicates that the p85
subunit of PI3K associates with 2B4 ~3 min following NK activation
and dissociates sometime between 10 and 20 min. The observed
association between 2B4 and the p85 subunit of PI3K implies a role for
2B4 in the induction of PI3K activity and the subsequent generation of
phosphorylated membrane lipids. To verify that the 2B4·p85
complex has associated enzymatic activity, we immunoprecipitated
2B4·p85 complexes from NK cells before and after 2B4 stimulation and
determined the ability of the complexes to generate phospholipid
products (Fig. 2B). A lipid substrate (phosphatidylinositol
4,5-bisphosphate) was added to the immunoprecipitated complexes in the
presence of [ Wortmannin Prevents the Association of 2B4 and
SAP/SH2D1A--
To investigate further the role
of PI3K following 2B4 activation, we studied the effect of wortmannin
on the association between 2B4 and SAP/SH2D1A (Fig.
3A). NK cells obtained from
healthy individuals were left unstimulated or briefly stimulated with
anti-2B4 and IL-2, and the lysates were harvested at 5 min. As
expected, because 2B4 is phosphorylated following activation (Fig.
1A), 2B4 and SAP/SH2D1A were associated in stimulated NK
cells, however, the pretreatment of cells with PI3K inhibitors but not
with other kinase inhibitors resulted in a loss of this association.
Because SAP/SH2D1A has previously been shown to associate only with
phosphorylated 2B4 (34), we next determined the effect of wortmannin on
2B4 phosphorylation. NK cells from healthy individuals were pretreated with wortmannin and then activated with anti-2B4 to determine whether
2B4 phosphorylation was altered. In normal NK cells, wortmannin did not
alter the phosphorylation of 2B4 at 3 min or the dephosphorylation of
2B4 that occurred within 5 min (Fig. 2A). However, in
XLP-NK cells, the presence of wortmannin resulted in significantly less phosphorylated 2B4 at both 3 and 5 min, suggesting that
dephosphorylation of 2B4 was occurring faster in XLP cells. These
observed differences between healthy and XLP NK cells were not because
of differences in the phenotype of the cells nor the levels of 2B4
expression (Fig. 3C). Together, these data demonstrate a
critical and functional role for PI3K in the recruitment of SAP/SH2D1A
to 2B4.
NK Cells with a Mutation of SAP/SH2D1A Have Defects in Activation
and Cytotoxicity--
In the experiments described above, we
determined that the inhibition of PI3K activity prevents an association
of SAP/SH2D1A with 2B4, and we showed that NK cells with a mutation of
SAP/SH2D1A lack PI3K enzymatic activity. To assess the functional
significance of abnormal PI3K signaling, we established NK cytotoxicity
assays using cells derived from normal controls and an XLP patient. We showed previously that NK cells carrying the R55L mutation in SAP/SH2D1A have defective cytotoxicity when tested against K562 target
cells (23). In those experiments, the reduction of killing by freshly
isolated (uncultured) NK cells was a consequence of fewer (CD3-CD56+)
NK cells present in XLP males. By using a stringent purification method
for selecting NK cells and by culturing them in high dose IL-2, we have
since been able to reliably generate CD3-CD56+ NK populations of >90%
purity from both healthy volunteers and an XLP patient (Fig.
4A). We compared the cytotoxic
function of these effector cells, both normal and XLP-derived, against K562 and Raji targets with or without 2B4 activation. Surprisingly, NK
cytotoxicity against K562 cells was not significantly different between
the two groups (Fig. 4B), suggesting that IL-2 cultured NK
cells from XLP patients are fully capable of killing MHC class I-deficient/low target cells. However, when tested against Raji targets
that express surface MHC class I, NK cells from normal controls
exhibited more cytotoxicity than XLP NK cells (Fig. 4C, p = 0.002). Moreover, when NK cells were activated with
anti-2B4, the differences in cytotoxicity were significantly more
apparent against both K562 (Fig. 4D, p < 0.001) and Raji (Fig. 4E, p < 0.0001)
cells. These data indicate that XLP-derived NK cells kill MHC class
I-deficient target cells in normal fashion but display diminished
cytotoxicity against cells expressing MHC class I. In addition, as
previously reported, XLP-derived NK cells manifest a significant defect
in 2B4-activated cytotoxicity.
Inhibition of PI3K Diminishes the Cytotoxicity of Normal but Not
XLP-derived NK Cells--
Using the system noted above, we
investigated the effect of PI3K inhibitors on the cytotoxicity of
normal and XLP-derived NK cells. NK cells were incubated in the
presence or absence of PI3K inhibitors prior to cytotoxicity assays
performed with or without 2B4 ligation. We found that both wortmannin
and LY294002 significantly reduced the cytotoxicity of normal NK cells
against K562 target cells with or without 2B4 activation (Fig. 5,
A and C, *, p < 0.0001 in all
cases comparing CM alone with wortmannin or LY294002). However, the
reduction in cytotoxicity was far less significant in NK cells that
carry the XLP mutation (Fig.
5A, **,
p = 0.018, and C, **,
p = 0.036). Against Raji target cells, normal NK cells
were also significantly inhibited by wortmannin or LY294002 (Figs. 5,
B and D, *, p < 0.0001 in all cases), but the inhibition of XLP-derived NK cytotoxicity
was insignificant (Fig. 5, B, **,
p = 0.18, and D, **, p = 0.17). These findings suggest that a mutation of SAP/SH2D1A partially
conceals the effect that PI3K inhibitors have on NK cytotoxicity.
We have investigated the role of PI3K in 2B4-mediated signal
transduction following NK cell activation. In agreement with previous
reports (12, 13), we found that 2B4 is phosphorylated ~2 min after
2B4 stimulation, and we showed that phosphorylation of 2B4 is followed
first by the association of PI3K at ~3 min and then by the
association of SAP/SH2D1A at 5 min. These kinetics of association are
consistent with a previous report (34) that SAP/SH2D1A interacts only
with the phosphorylated form of 2B4. Interestingly, we found that by
inhibiting PI3K activity either with wortmannin or with LY294002, the
association of SAP/SH2D1A to 2B4 was prevented, implying that PI3K
either directly or indirectly facilitates the binding of SAP/SH2D1A to
2B4. In an XLP patient with an inactivating mutation of SAP/SH2D1A, 2B4
and PI3K continued to be associated (Fig. 2C), but PI3K
activity was not present (Fig. 2B), suggesting that
conversely PI3K activity is dependent on functioning SAP/SH2D1A. These
findings taken together imply a complex sequence of events following
2B4 stimulation where SAP/SH2D1A-2B4 association is dependent on PI3K
activity and where PI3K activity is dependent on functional SAP/SH2D1A.
These events suggest that SAP/SH2D1A has multiple functions beyond
simply binding to phosphorylated 2B4 and may also bind to one or
more other phosphotyrosine motifs that facilitate PI3K activity. For
instance, it was shown previously that LAT constitutively associates
with 2B4, and that the ligation of 2B4 leads to the phosphorylation of
LAT and the recruitment of other intracellular proteins to the
LAT·2B4 complex (17). It has also been suggested in T cells that the
p85 subunit of PI3K associates with LAT directly or with the
tyrosine-phosphorylated immunoreceptor tyrosine-based motif of
the FcR PI3K and its downstream products have been implicated in basic cell
processes that influence NK cytotoxicity including chemotaxis (33),
trafficking of perforin/granzyme B (29), and plasma membrane
reorganization (36). It is unclear as to which of these activities is
most important in the context of 2B4-mediated NK cytotoxicity, because
all three mechanisms may play critical roles. For example, the
recruitment and activation of PI3K may affect NK plasma membrane
reorganization. In support of this hypothesis, previous work (37, 38)
indicates that CD2, which is closely related to 2B4, assists in
adhesion between T cells and antigen-presenting cells, and that the
adhesion-promoting properties of CD2 are mediated by the formation of
lipid rafts. Raft formation occurred in both activated T cells, a
subset of which also express 2B4, (38, 39) and in NK cells (40, 41),
and interestingly, it was dependent on PI3K activity (42). Thus, 2B4
stimulation and the downstream functions of both SAP/SH2D1A and PI3K
may assist in lipid raft formation, which is critical for signaling and
cytotoxicity. In addition, defects of the perforin/granzyme B pathway
would certainly affect NK cell cytotoxicity. In this regard, Djeu and colleagues (29, 43) have shown that intracellular redistribution of
perforin granules is dependent on PI3K and its downstream effectors, MEK and extracellular signal-regulated kinase-2 (ERK2).
In addition to preventing the association of 2B4
with SAP/SH2D1A, wortmannin and LY294002 were able to inhibit
significantly the cytotoxicity of normal NK cells (Fig. 5). This
inhibition was much less apparent or absent in NK cells from a patient
with XLP, suggesting that a block in signaling at the stage of PI3K was
made redundant by a block at the stage of SAP/SH2D1A association. The
implication of this redundancy is that PI3K and SAP/SH2D1A participate
serially in the same signaling pathway. Therefore, we propose a model
whereby the activation of PI3K allows SAP/SH2D1A to associate with 2B4,
and we suggest that this association is critical for NK cell effector
function. In XLP patients, SAP/SH2D1A is unable to bind to 2B4. Thus,
any inhibition of PI3K has no further impact on cytotoxicity, and we
conclude that the major effect of wortmannin and LY294002 on blocking
cytotoxicity occurs via preventing the association of SAP with 2B4.
This conclusion is also consistent with our finding that NK cells
carrying mutated SAP/SH2D1A cannot induce PI3K activity following 2B4
stimulation (Fig. 3), although the precise mechanism is unknown.
During investigation of the role of PI3K in NK cytotoxicity, we found
as others have (18, 24) that NK cells expressing mutated SAP/SH2D1A
lyse K562 target cells as efficiently as normal NK cells. The
differences in cytotoxicity between normal and XLP cells only appeared
when lymphokine-activated killer-sensitive (NK-resistant) Raji target
cells were used or when NK cells were activated with anti-2B4. One
difference between K562 cells and Raji cells is that the K562 cells
lack or have very low MHC class I surface expression, whereas Raji
cells express HLA A, B, C (44). Taken together, one interpretation of
these observations is that NK cells from XLP patients are fully capable
of killing MHC class I-deficient targets, but because they lack
functional SAP/SH2D1A, they are unable to achieve the broader killing
repertoire of 2B4-activated NK cells. Because MHC class I-deficient
target cells are likely to generate fewer NK inhibitory signals,
unstimulated NK cells are still able to efficiently lyse them. We
speculate that different viral infections may generate different
expression levels of MHC class I on infected cells and that clinically
apparent XLP develops only when containment of viral replication
requires 2B4-dependent elimination of infected targets.
We thank members of the Tan laboratory,
especially Erica Lee and Xiaoxia Wang for technical advice and
assistance. We also thank Dr. Henry Pabst for providing patient
samples and Drs. Mike Gold and C. Bruce Verchere for reviewing the manuscript.
*
This work was supported by the Canadian Institutes of Health
Research and the British Columbia's Children's Hospital Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
This paper is dedicated to the Kaska people of northwestern Canada.
§
To whom correspondence should be addressed: Dept. of Pathology & Laboratory Medicine, BC's Children's Hospital, 4480 Oak St., Rm. 2G5,
Vancouver, BC V6H 3V4, Canada. Tel.: 604-875-3605; Fax: 604-875-3777;
E-mail: roo@interchange.ubc.ca.
Published, JBC Papers in Press, January 28, 2002, DOI 10.1074/jbc.M112029200
The abbreviations used are:
NK, natural killer;
SAP/SH2D1A, signaling lymphocytic activation molecule-associated
protein;
IL-2, interleukin-2;
PI3K, phosphoinositide 3-kinase;
MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase
kinase;
ERK, extracellular signal-regulated kinase;
MHC, major
histocompatibility complex.
Association of the X-linked Lymphoproliferative Disease Gene
Product SAP/SH2D1A with 2B4, a Natural Killer Cell-activating Molecule,
Is Dependent on Phosphoinositide 3-Kinase*
and
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
, and increase calcium flux, phosphoinositol turnover, and perforin degranulation. (7-9).
,
,
, or
) and a regulatory (p85
, p85
, p101, or p55
) subunit (25, 26). In the case of
tyrosine-phosphorylated membrane receptors such as 2B4, PI3K activation
begins with the formation of a high affinity interaction between SH2
domains of either p85
or p85
and tyrosine-phosphorylated
cytoplasmic domains of the membrane receptor. The association of the
p85 subunit recruits the p110 catalytic subunit, which can
phosphorylate the D-3 position of the inositol ring of phosphoinositol
lipids. The phosphorylated inositol lipids and other metabolites
including phosphatidylinositol 3,4-biphosphate are termed
3'-phosphoinositides and act as second messengers in signal
transduction. A role for PI3K and 3'-phosphoinositides is
suggested because PI3K is known to participate in
antibody-dependent cellular cytotoxicity of NK cells (27,
28), and inhibition of PI3K activity has been shown to decrease the
cellular cytotoxicity of an NK cell line, NK92 (29).
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
5 M
2-mercaptoethanol, and 1000 IU/ml IL-2 (Teceleukin, Roche Molecular Biochemicals). These cells were used for all experiments and represent an IL-2-activated NK or lymphokine-activated killer cell phenotype. Prior to experiments, NK cells were rested for 6 h in AIM-V
serum-free medium (Invitrogen). For inhibition experiments, chemical
inhibitors (100 nM wortmannin, 100 µM
LY294002, 25 µM PD98059, 100 µM protein kinase C inhibitor (residues 19-27 of sequence RFARKGALRQKNV), or 100 µM PP2) were added for 30 min at 37 °C. The
concentrations for wortmannin and LY294002 were determined by dose
response experiments (data not shown). For activation, NK cells were
incubated for 5 min with mAb C1.7 and IL-2 (100 IU/ml).
-radiation counting. Specific lysis
was calculated as described previously (23).
-32P]ATP (Amersham
Biosciences) and incubated for 10 min at 25 °C. MgCl2
(20 mM) was then added to this mixture for an additional 15 min. The reaction was stopped by the addition of 20 µl of 6 N HCl and 160 µl of CHCl3:MeOH (1:1). The
organic phase was separated from the chloroform layer, and 50 µl was
spotted on thin layer chromatography aluminum Silica Gel 60 F254 precoated sheets (Sigma). Thin layer chromatography
plates were developed and resolved in CHCl3:MeOH:H2O:NH4OH
(60:47:11.3:2), left to dry, and phosphatidylinositol 1,4,5-trisphosphate products were visualized by autoradiography.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (27K):
[in a new window]
Fig. 1.
NK cell activation by anti-2B4 results in 2B4
phosphorylation and the recruitment of SAP/SH2D1A in normal but not XLP
NK cells. A, phosphorylation of 2B4 following
activation. NK cells were incubated at 37 °C in CM alone (lane
1), CM with mouse IgG (lane 2), or CM with mAb C1.7 and
IL-2 (lane 3). Cell lysates were collected after 2 min,
immunoprecipitated (IP) with anti-2B4, and immunoblotted
(IB) with antiphosphotyrosine. B, SAP/SH2D1A
associates maximally with 2B4 following stimulation with anti-2B4 and
IL-2. NK cells were incubated at 37 °C for 5 min under the indicated
conditions. Cell lysates were immunoprecipitated with anti-SAP/SH2D1A
and immunoblotted with mAb C1.7. C, time course of
SAP/SH2D1A-2B4 association. NK cells were incubated at 37 °C in CM
(lane 1), or in CM with mAb C1.7 and IL-2 (lanes
2-6, respectively) for indicated times before cell lysis. Cell
lysates were immunoprecipitated with anti-2B4 and immunoblotted with
anti-SAP/SH2D1A. D, mutated SAP/SH2D1A does not
associate with 2B4. NK cell lysates from normal controls or an XLP
patient were immunoprecipitated with anti-2B4 and immunoblotted with
anti-SAP/SH2D1A. E, expression of SAP/SH2D1A in
normal and XLP NK cells. Cell lysates from were resolved by SDS-PAGE
and immunoblotted with anti-SAP/SH2D1A. WB, Western blot.
The molecular masses are indicated by the markers on the
left.
-32P]ATP, and the lipid products were
separated by thin layer chromatography and visualized by
autoradiography. To determine specifically the role of SAP/SH2D1A in
the activation of PI3K, we performed these experiments using normal and
XLP-derived NK cells. After 2B4 stimulation, immunoprecipitates derived
from normal controls were able to generate phosphoinositide 3' products
(phosphatidylinositol 3,4,5-trisphosphate), indicating that PI3K
associated with 2B4 is functionally active (Fig. 2B,
lane 3). As expected, the addition of wortmannin inhibited this kinase activity (Fig. 2B, lane 2). However,
in contrast to cells derived from healthy subjects, immunoprecipitates
from NK cells expressing a mutated form of SAP/SH2D1A lacked any PI3K activity (Fig. 2B, lane 6). The loss of PI3K
activity was not because of a lack of association between 2B4 and PI3K,
although this association was weaker in XLP-derived NK cells (Fig.
2C). We also investigated the effect of PI3K inhibitors,
wortmannin or LY294002, on the association of 2B4 with PI3K p85 itself.
The pretreatment of NK cells with either inhibitor did not prevent the
association of the p85 subunit with 2B4 (Fig. 2D).
Therefore, the expression of mutated SAP/SH2D1A alters the association
and/or function of PI3K in NK cells, and PI3K activity is absent
following 2B4-mediated activation of XLP-derived NK cells.

View larger version (23K):
[in a new window]
Fig. 2.
2B4 associates with the p85 subunit of PI3K
and activated PI3K recruits SAP/SH2D1A to 2B4. A,
PI3K associates with 2B4 in activated NK cells. NK cells were incubated
in CM alone (lane 1) or with mAb C1.7 and IL-2 for the
indicated times (lanes 2-5, respectively) before cell
lysis. Lysates were immunoprecipitated (IP) with mAb C1.7
and immunoblotted (IB) with anti-p85 mAb. B,
PI3K activity is absent in NK cells carrying a mutation in SAP/SH2D1A.
NK cells were isolated and prepared as described above. The cells were
treated as indicated, and cell lysates were immunoprecipitated with
anti-2B4 and co-incubated with phosphatidylinositol 4,5-bisphosphate in
the presence of [
-32P]ATP. The arrows
indicate either the PI3K products, phosphatidylinositol
1,4,5-trisphosphate (PIP3), or the original spot
(Orig.). C, Activated 2B4 recruits PI3K in NK
cells of XLP patient. NK cells were incubated as indicated, and cell
lysates were immunoprecipitated with anti-2B4 and immunoblotted with
anti-p85 mAb. D, the inhibition of PI3K does not
prevent association of 2B4 with PI3K. NK cells were treated as
indicated. The cells were washed and further incubated for 5 min at
37 °C in CM alone (lane 1) or with mAb C1.7 and IL-2
(lanes 2-5). Cell lysates were immunoprecipitated with mAb
C1.7 and immunoblotted with anti-p85 mAb.

View larger version (29K):
[in a new window]
Fig. 3.
Wortmannin prevents the association of 2B4
and SAP/SH2D1A. A, inhibition of PI3K prevents the
association of 2B4 with SAP/SH2D1A. NK cells were treated as indicated.
The cells were washed and further incubated for 5 min at 37 °C in CM
(Unstim.) or in CM with mAb C1.7 and IL-2
(Stim.). Cell lysates were immunoprecipitated with anti-2B4
and immunoblotted with anti-SAP/SH2D1A. B, the
inhibition of PI3K dephosphorylate-activated 2B4. NK cells were
untreated or treated with wortmannin, washed, and further incubated for
3 and 5 min at 37 °C in either CM alone or with mAb C1.7 and IL-2.
Cell lysates were immunoprecipitated with anti-2B4 and immunoblotted
with antiphosphotyrosine-horseradish peroxidase conjugate
(anti-phosphotyrosine). C, phenotype of NK cells.
Representative fluorescence-activated cell sorter analysis of NK cells
obtained from an XLP patient or from healthy controls. Cells were
co-stained with anti-2B4 fluorescein isothiocyanate and anti-CD56
allophycocyanin (APC) (upper panels) or with
anti-CD3 fluorescein isothiocyanate and anti-CD56 allophycocyanin (APC)
(lower panels) and analyzed by flow cytometry.

View larger version (20K):
[in a new window]
Fig. 4.
NK cells with a mutation of SAP/SH2D1A have
defects in activation and cytotoxicity. A,
phenotype of effector cells. Representative immunophenotype of NK cells
obtained from an XLP patient or from a healthy control. Cells were
co-stained with anti-CD3 fluorescein isothiocyanate and anti-CD56 and
analyzed on a FACSCalibur flow cytometer (BD PharMingen) using
CellquestTM software. B-E, a comparison of
cytotoxicity between normal and XLP-derived NK cells. NK cells from
normal donors (n = 6) (
or
) or an XLP patient
(
or
) were cultured in CM with 1000 IU/ml IL-2 for 14 days.
Cells were washed and incubated in AIM-V medium for 6 h
prior to assays. NK cells were incubated in CM alone (B and
C) or in CM with mAb C1.7 plus 100 IU/ml IL-2 (D
and E), and the NK cytotoxicity was measured in chromium
release assays. Target cells used were K562 (B and
D) or Raji (C and E). All assays were
performed in triplicate and on at least three separate occasions. Each
data point is the mean value of the repeated experiments, and the error
bars refer to the mean ± S.D. generated from the three
independent assays. Student's t test was used to calculate
p values. *, p = 0.002;
**, p = 0.0006; and ***,
p < 0.0001.

View larger version (29K):
[in a new window]
Fig. 5.
Inhibition of PI3K diminishes the
cytotoxicity of normal but not XLP-derived NK cells. The effect of
the PI3K inhibition on NK cytotoxicity. NK cells were isolated and
prepared as described above. The cells were left untreated
(CM) or treated with Lck inhibitor (PP2),
wortmannin (Wort), or LY294002 (LY) for 30 min at
37 °C. NK cells were washed and incubated for 5 min in CM
(A and B) or CM with C1.7 plus IL-2 (C
and D) before NK cytotoxicity was measured in chromium
release assays at a 20:1 effector to target ratio. Target cells used
were K562 (A and C) or Raji (B and
D). All assays were performed in triplicate and on at least
three separate occasions. Each data point is the mean value of the
repeated experiments, and the error bars refer to the mean ± S.D.
generated from the three independent assays. Student's t
test was used to calculate p values. *,
p < 0.0001 (A-D); **,
p = 0.018 (A); **,
p < 0.18 (B); **,
p = 0.036 (C); **,
p = 0.17 (D).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-chain via the SH2 domains of p85 (35). Thus, SAP/SH2D1A may
facilitate PI3K activation through its association with LAT rather than
2B4 (17). Nevertheless, the above findings argue that PI3K plays an
important role in mediating the cytotoxicity of 2B4-activated NK cells.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
Supported by the Michael Smith Foundation for Health Research.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
1.
Biron, C. A.,
Nguyen, K. B.,
Pien, G. C.,
Cousens, L. P.,
and Salazar-Mather, T. P.
(1999)
Annu. Rev. Immunol.
17,
189-220[CrossRef][Medline]
[Order article via Infotrieve] 2.
Trinchieri, G.
(1995)
Semin. Immunol.
7,
83-88[CrossRef][Medline]
[Order article via Infotrieve] 3.
Moretta, A.,
Bottino, C.,
Vitale, M.,
Pende, D.,
Cantoni, C.,
Mingari, M. C.,
Biassoni, R.,
and Moretta, L.
(2001)
Annu. Rev. Immunol.
19,
197-223[CrossRef][Medline]
[Order article via Infotrieve] 4.
Lanier, L. L.
(1998)
Annu. Rev. Immunol.
16,
359-393[CrossRef][Medline]
[Order article via Infotrieve] 5.
Garni-Wagner, B. A.,
Purohit, A.,
Mathew, P. A.,
Bennett, M.,
and Kumar, V.
(1993)
J. Immunol.
151,
60-70[Abstract] 6.
Mathew, P. A.,
Garni-Wagner, B. A.,
Land, K.,
Takashima, A.,
Stoneman, E.,
Bennett, M.,
and Kumar, V.
(1993)
J. Immunol.
151,
5328-5337[Abstract] 7.
Nakajima, H.,
Cella, M.,
Langen, H.,
Friedlein, A.,
and Colonna, M.
(1999)
Eur. J. Immunol.
29,
1676-1683[CrossRef][Medline]
[Order article via Infotrieve] 8.
Brown, M. H.,
Boles, K.,
van der Merwe, P. A.,
Kumar, V.,
Mathew, P. A.,
and Barclay, A. N.
(1998)
J. Exp. Med.
188,
2083-2090 9.
Chuang, S. S.,
Kim, M. H.,
Johnson, L. A.,
Albertsson, P.,
Kitson, R. P.,
Nannmark, U.,
Goldfarb, R. H.,
and Mathew, P. A.
(2000)
Immunology
100,
378-383[CrossRef][Medline]
[Order article via Infotrieve] 10.
Stepp, S. E.,
Schatzle, J. D.,
Bennett, M.,
Kumar, V.,
and Mathew, P. A.
(1999)
Eur. J. Immunol.
29,
2392-2399[CrossRef][Medline]
[Order article via Infotrieve] 11.
Nakajima, H.,
and Colonna, M.
(2000)
Hum. Immunol.
61,
39-43[CrossRef][Medline]
[Order article via Infotrieve] 12.
Tangye, S. G.,
Lazetic, S.,
Woollatt, E.,
Sutherland, G. R.,
Lanier, L. L.,
and Phillips, J. H.
(1999)
J. Immunol.
162,
6981-6985 13.
Watzl, C.,
Stebbins, C. C.,
and Long, E. O.
(2000)
J. Immunol.
165,
3545-3548 14.
Bakker, A. B., Wu, J.,
Phillips, J. H.,
and Lanier, L. L.
(2000)
Hum. Immunol.
61,
18-27[CrossRef][Medline]
[Order article via Infotrieve] 15.
Schatzle, J. D.,
Sheu, S.,
Stepp, S. E.,
Mathew, P. A.,
Bennett, M.,
and Kumar, V.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
3870-3875 16.
Sylla, B. S.,
Murphy, K.,
Cahir-McFarland, E.,
Lane, W. S.,
Mosialos, G.,
and Kieff, E.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
7470-7475 17.
Bottino, C.,
Augugliaro, R.,
Castriconi, R.,
Nanni, M.,
Biassoni, R.,
Moretta, L.,
and Moretta, A.
(2000)
Eur. J. Immunol.
30,
3718-3722[CrossRef][Medline]
[Order article via Infotrieve] 18.
Tangye, S. G.,
Phillips, J. H.,
Lanier, L. L.,
and Nichols, K. E.
(2000)
J. Immunol.
165,
2932-2936 19.
Coffey, A. J.,
Brooksbank, R. A.,
Brandau, O.,
Oohashi, T.,
Howell, G. R.,
Bye, J. M.,
Cahn, A. P.,
Durham, J.,
Heath, P.,
Wray, P.,
Pavitt, R.,
Wilkinson, J.,
Leversha, M.,
Huckle, E.,
Shaw-Smith, C. J.,
Dunham, A.,
Rhodes, S.,
Schuster, V.,
Porta, G.,
Yin, L.,
Serafini, P.,
Sylla, B.,
Zollo, M.,
Franco, B.,
Bentley, D. R.,
et al..
(1998)
Nat. Genet.
20,
129-135[CrossRef][Medline]
[Order article via Infotrieve] 20.
Sayos, J., Wu, C.,
Morra, M.,
Wang, N.,
Zhang, X.,
Allen, D.,
van Schaik, S.,
Notarangelo, L.,
Geha, R.,
Roncarolo, M. G.,
Oettgen, H., De,
Vries, J. E.,
Aversa, G.,
and Terhorst, C.
(1998)
Nature
395,
462-469[CrossRef][Medline]
[Order article via Infotrieve] 21.
Nichols, K. E.,
Harkin, D. P.,
Levitz, S.,
Krainer, M.,
Kolquist, K. A.,
Genovese, C.,
Bernard, A.,
Ferguson, M.,
Zuo, L.,
Snyder, E.,
Buckler, A. J.,
Wise, C.,
Ashley, J.,
Lovett, M.,
Valentine, M. B.,
Look, A. T.,
Gerald, W.,
Housman, D. E.,
and Haber, D. A.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13765-13770 22.
Parolini, S.,
Bottino, C.,
Falco, M.,
Augugliaro, R.,
Giliani, S.,
Franceschini, R.,
Ochs, H. D.,
Wolf, H.,
Bonnefoy, J. Y.,
Biassoni, R.,
Moretta, L.,
Notarangelo, L. D.,
and Moretta, A.
(2000)
J. Exp. Med.
192,
337-346 23.
Benoit, L.,
Wang, X.,
Pabst, H. F.,
Dutz, J.,
and Tan, R.
(2000)
J. Immunol.
165,
3549-3553 24.
Nakajima, H.,
Cella, M.,
Bouchon, A.,
Grierson, H. L.,
Lewis, J.,
Duckett, C. S.,
Cohen, J. I.,
and Colonna, M.
(2000)
Eur. J. Immunol.
30,
3309-3318[CrossRef][Medline]
[Order article via Infotrieve] 25.
Rameh, L. E.,
and Cantley, L. C.
(1999)
J. Biol. Chem.
274,
8347-8350 26.
Fruman, D. A.,
Meyers, R. E.,
and Cantley, L. C.
(1998)
Annu. Rev. Biochem.
67,
481-507[CrossRef][Medline]
[Order article via Infotrieve] 27.
Kanakaraj, P.,
Duckworth, B.,
Azzoni, L.,
Kamoun, M.,
Cantley, L. C.,
and Perussia, B.
(1994)
J. Exp. Med.
179,
551-558 28.
Bonnema, J. D.,
Karnitz, L. M.,
Schoon, R. A.,
Abraham, R. T.,
and Leibson, P. J.
(1994)
J. Exp. Med.
180,
1427-1435 29.
Jiang, K.,
Zhong, B.,
Gilvary, D. L.,
Corliss, B. C.,
Hong-Geller, E.,
Wei, S.,
and Djeu, J. Y.
(2000)
Nat. Immunol.
1,
419-425[CrossRef][Medline]
[Order article via Infotrieve] 30.
al-Aoukaty, A.,
Rolstad, B.,
and Maghazachi, A. A.
(1999)
J. Immunol.
162,
3249-3255 31.
Valiante, N. M.,
and Trinchieri, G.
(1993)
J. Exp. Med.
178,
1397-1406 32.
Dutz, J. P.,
Benoit, L.,
Wang, X.,
Demetrick, D. J.,
Junker, A.,
de Sa, D.,
and Tan, R.
(2001)
Blood
97,
95-100 33.
Servant, G.,
Weiner, O. D.,
Herzmark, P.,
Balla, T.,
Sedat, J. W.,
and Bourne, H. R.
(2000)
Science
287,
1037-1040 34.
Sayos, J.,
Nguyen, K. B., Wu, C.,
Stepp, S. E.,
Howie, D.,
Schatzle, J. D.,
Kumar, V.,
Biron, C. A.,
and Terhorst, C.
(2000)
Int. Immunol.
12,
1749-1757 35.
Gibbins, J. M.,
Briddon, S.,
Shutes, A.,
van Vugt, M. J.,
van de Winkel, J. G.,
Saito, T.,
and Watson, S. P.
(1998)
J. Biol. Chem.
273,
34437-34443 36.
Corvera, S.,
and Czech, M. P.
(1998)
Trends Cell Biol.
8,
442-446[CrossRef][Medline]
[Order article via Infotrieve] 37.
Yashiro-Ohtani, Y.,
Zhou, X. Y.,
Toyo-Oka, K.,
Tai, X. G.,
Park, C. S.,
Hamaoka, T.,
Abe, R.,
Miyake, K.,
and Fujiwara, H.
(2000)
J. Immunol.
164,
1251-1259 38.
Grakoui, A.,
Bromley, S. K.,
Sumen, C.,
Davis, M. M.,
Shaw, A. S.,
Allen, P. M.,
and Dustin, M. L.
(1999)
Science
285,
221-227 39.
Dustin, M. L.,
and Shaw, A. S.
(1999)
Science
283,
649-650 40.
Davis, D. M.,
Chiu, I.,
Fassett, M.,
Cohen, G. B.,
Mandelboim, O.,
and Strominger, J. L.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
15062-15067 41.
Lou, Z.,
Jevremovic, D.,
Billadeau, D. D.,
and Leibson, P. J.
(2000)
J. Exp. Med.
191,
347-354 42.
Moran, M.,
and Miceli, M. C.
(1998)
Immunity
9,
787-796[CrossRef][Medline]
[Order article via Infotrieve] 43.
Wei, S.,
Gamero, A. M.,
Liu, J. H.,
Daulton, A. A.,
Valkov, N. I.,
Trapani, J. A.,
Larner, A. C.,
Weber, M. J.,
and Djeu, J. Y.
(1998)
J. Exp. Med.
187,
1753-1765 44.
Johnson, D. R.
(2000)
Hum. Immunol.
61,
389-396[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
J. C. D. Wiseman, L. L. Ma, K. J. Marr, G. J. Jones, and C. H. Mody Perforin-Dependent Cryptococcal Microbicidal Activity in NK Cells Requires PI3K-Dependent ERK1/2 Signaling J. Immunol., May 15, 2007; 178(10): 6456 - 6464. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Alvarez-Errico, J. Sayos, and M. Lopez-Botet The IREM-1 (CD300f) Inhibitory Receptor Associates with the p85{alpha} Subunit of Phosphoinositide 3-Kinase J. Immunol., January 15, 2007; 178(2): 808 - 816. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Eissmann and C. Watzl Molecular Analysis of NTB-A Signaling: A Role for EAT-2 in NTB-A-Mediated Activation of Human NK Cells. J. Immunol., September 1, 2006; 177(5): 3170 - 3177. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Tassi and M. Colonna The Cytotoxicity Receptor CRACC (CS-1) Recruits EAT-2 and Activates the PI3K and Phospholipase C{gamma} Signaling Pathways in Human NK Cells J. Immunol., December 15, 2005; 175(12): 7996 - 8002. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Chen, A. K. Tai, M. Lin, F. Chang, C. Terhorst, and B. T. Huber Signaling Lymphocyte Activation Molecule-Associated Protein Is a Negative Regulator of the CD8 T Cell Response in Mice J. Immunol., August 15, 2005; 175(4): 2212 - 2218. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Eissmann, L. Beauchamp, J. Wooters, J. C. Tilton, E. O. Long, and C. Watzl Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244) Blood, June 15, 2005; 105(12): 4722 - 4729. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Aoukaty and R. Tan Role for Glycogen Synthase Kinase-3 in NK Cell Cytotoxicity and X-Linked Lymphoproliferative Disease J. Immunol., April 15, 2005; 174(8): 4551 - 4558. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Chen, F. Relouzat, R. Roncagalli, A. Aoukaty, R. Tan, S. Latour, and A. Veillette Molecular Dissection of 2B4 Signaling: Implications for Signal Transduction by SLAM-Related Receptors Mol. Cell. Biol., June 15, 2004; 24(12): 5144 - 5156. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sanzone, M. Zeyda, M. D. Saemann, M. Soncini, W. Holter, G. Fritsch, W. Knapp, F. Candotti, T. M. Stulnig, and O. Parolini SLAM-associated Protein Deficiency Causes Imbalanced Early Signal Transduction and Blocks Downstream Activation in T Cells from X-linked Lymphoproliferative Disease Patients J. Biol. Chem., August 8, 2003; 278(32): 29593 - 29599. [Abstract] [Full Text] [PDF] |
||||
| ||||||